What one share of Pelthos Therapeutics holds
Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S.
Pelthos Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $13.26 |
|---|---|
| Profit | −$26.46 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$13.05 |
| Cash and investments | $6.51 |
| Book value | −$0.40 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$57.82 | — | — | — | — |
| 2024 | $0.00 | −$14.27 | $0.00 | −$10.39 | — | −$4.45 |
| 2025 | $8.93 | −$23.04 | $0.05 | −$12.07 | — | $12.02 |
Common questions about Pelthos Therapeutics
How much does one share of Pelthos Therapeutics earn?
Over the last 12 months, Pelthos Therapeutics lost $26.46 for each share on $13.26 of sales.
Does Pelthos Therapeutics pay a dividend?
Pelthos Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Pelthos Therapeutics’s book value per share?
Pelthos Therapeutics’s book value is negative (−$0.40 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Pelthos Therapeutics have?
Each share of Pelthos Therapeutics has $6.51 of cash and investments, as of June 30, 2026.
What is Pelthos Therapeutics’s free cash flow per share?
−$13.05 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.